Analyst Coverage
Diamond Equity Research
Imugene Limited: Update Note
Research as a Service (RaaS)
ASX:IMU RaaS Update Report
Bell Potter
Imugene (IMU) Azer-cel cohort 3 enrols first patient
Diamond Equity Research
Resumption of Coverage: Imugene Ltd
Research as a Service (RaaS)
ASX:IMU RaaS Initiation Report
Bioshares
Imugene Data Continues to Impress
Diamond Equity Research
Imugene Limited – Announces Up to A$46 Million Financing, Achieves First Intratumoural onCARlytics Dosing Milestone, and Opens First Australian Azer-cel Trial Site for Relapsed or Refractory DLBCL
Diamond Equity Research
Sustained Momentum with Key Clinical Advancements and Robust Financial Profile, With Numerous Upcoming Potential Catalysts
Diamond Equity Research
Receives Orphan Drug Designation for Bile Tract CancerTherapy and Reports Encouraging Blood Cancer Trial Outcomes
Lodge Partners
Research Report Imugene Limited (ASX: IMU)
Bioshares
Imugene Delivers Positive Early Data with Azer-Cel Technology Acquired Last Year
Roth Capital Partners